Sunday 18 October 2026 Export CCCC’s income statement to Excel — free account

C4 Therapeutics, Inc.

C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.

2.77 0.01 −0.36%

Follow CCCC

Alert me

Market cap: $342.0M
P/E: 0.0×
Fwd P/E: −4.1×
Dividend yield: —
F-score: 4/9
Altman Z: −2.16
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	1	—	—	—	—	—	—	—	—	—

Insider Ownership 13.45%

Capital & Financial Ratios $m

Market Cap 342.01

Revenue 35.04

Net Income (101.42)

Free Cash Flow (85.39)

Net Debt (253.66)

Current Ratio 5.45

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.07)

P/S ratio 10.33

P/B ratio 1.46

Past 5Y EPS Growth —

This Y EPS Growth 33.00%

Next Y EPS Growth (10.95%)

Next Y revenue growth (26.56%)

Next 5Y EPS Growth 3.09%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 50.30%

10-year low 10-year high

P/B against its own 10 years 55.88%

10-year low 10-year high

EV/Sales against its own 10 years 34.62%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	254	245	249	254
Receivables	12	3	2	1
Inventory	—	—	—	—
Other	—	—	—	—
	271	258	258	263

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	43	45	33	48

Compound Annual Growth %

	10y	5y	3y
Sales	—	1.61%	4.95%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(1.79%)	(3.91%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	7	—	—	—
’25	7	6	11	11	36
’24	3	12	15	5	36
’23	4	3	11	3	21
’22	8	14	7	3	31
’21	7	10	9	20	46
’20	7	10	8	8	33

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(2)	—	—	—
’25	(33)	(12)	(31)	(22)	(99)
’24	(18)	(5)	(24)	(18)	(65)
’23	(33)	(19)	(31)	(24)	(107)
’22	(27)	(22)	(28)	(29)	(106)
’21	(25)	(18)	(18)	(26)	(87)
’20	(17)	(15)	(14)	(22)	(67)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(2)	—	—	—
’25	(33)	(12)	(32)	(22)	(99)
’24	(18)	(5)	(24)	(18)	(65)
’23	(34)	(19)	(31)	(24)	(109)
’22	(27)	(23)	(31)	(31)	(111)
’21	(25)	(19)	(18)	(26)	(88)
’20	(17)	(14)	(15)	(22)	(68)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.18)	—	—	—
’25	(0.37)	(0.37)	(0.44)	(0.18)	(1.27)
’24	(0.41)	(0.26)	(0.35)	(0.49)	(1.52)
’23	(0.71)	(0.73)	(0.55)	(0.68)	(2.67)
’22	(0.65)	(0.56)	(0.65)	(0.76)	(2.62)
’21	(0.49)	(0.51)	(0.51)	(0.31)	(1.82)
’20	(8.14)	(7.31)	(17.55)	23.79	(5.83)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	22.40	27.84	4.84	1.06	3.43	1.09	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	37.80	51.21	33.76	9.41	11.88	4.26
People
People	Employees	—	—	—	88	99	121	146	145	110	104
	Revenue/emp, $m	—	—	0.00	0.24	0.34	0.38	0.21	0.14	0.32	0.35
Income, $m
Income, $m	Revenue	—	—	19	21	33	46	31	21	36	36
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(16)	(33)	(67)	(84)	(128)	(131)	(105)	(105)
	EBT margin, %	—	—	(81.14)	(155.72)	(201.72)	(183.23)	(412.19)	(632.17)	(295.60)	(291.74)
	Net income	—	0	(16)	(34)	(66)	(84)	(128)	(132)	(105)	(105)
	Depreciation	—	—	4	2	2	4	3	(1)	(4)	(1)
Per share, $
Per share, $	Revenue	—	—	0.46	15.58	2.92	0.99	0.64	0.42	0.51	0.43
	Earnings	—	—	(0.57)	(24.85)	(5.83)	(1.82)	(2.62)	(2.67)	(1.52)	(1.27)
	Cash flow	—	—	(0.40)	40.54	(5.91)	(1.89)	(2.17)	(2.15)	(0.94)	(1.19)
	Capex	—	—	0.00	(0.94)	(0.06)	(0.03)	(0.11)	(0.03)	0.00	(0.01)
	Free cash flow	—	—	(0.40)	39.60	(5.97)	(1.92)	(2.28)	(2.19)	(0.94)	(1.20)
	Book value	—	—	0.74	(0.71)	24.70	8.46	5.92	4.96	3.11	3.10
	Shares, m	—	—	42	1	11	46	49	50	69	83
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	1.30	1.30	11.35	32.38	10.03	15.59	7.02	4.40
	P/B	—	—	0.00	0.00	1.34	3.81	1.08	1.32	1.16	0.62
	EV/Sales	—	—	(4.93)	(4.93)	0.48	25.89	1.51	4.28	0.67	(1.98)
	EV/FCF	—	—	2.66	2.66	(0.24)	(13.43)	(0.42)	(0.82)	(0.36)	0.72
Cash, $m
Cash, $m	Operating cash flow	—	—	(17)	56	(67)	(87)	(106)	(107)	(65)	(99)
	Capex	—	—	(3)	(1)	(1)	(1)	(5)	(2)	0	(1)
	Free cash flow	—	—	(17)	54	(68)	(88)	(111)	(109)	(65)	(99)
Balance, $m
Balance, $m	Working capital	—	—	100	63	337	274	243	228	213	225
	Total debt	—	—	14	14	11	12	11	—	—	—
	Net debt	—	—	(22)	(77)	(361)	(297)	(265)	(254)	(245)	(249)
	Shareholders’ equity	—	—	31	(1)	281	390	289	246	216	257
Returns, %
Returns, %	ROA	—	—	(32.91)	(32.16)	(25.59)	(18.50)	(27.34)	(32.82)	(29.01)	(29.63)
	ROIC	—	—	0.00	0.00	0.00	(55.54)	(329.60)	0.00	0.00	(894.58)
	ROE	—	—	25.15	44.41	(78.58)	(25.03)	(37.76)	(49.50)	(45.58)	(44.44)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AVIR Atea Pharmaceuticals, Inc.	$363.3M	— (loss-making)	— (loss-making)	+295.16% (above 0%: growing)	n/m	+85.53% (above 0%: growing)	0.00%	0.00%	Compare
FENC Adherex Technologies Inc.	$362.9M	— (loss-making)	31.4×	+85.18% (above 0%: growing)	n/m	+101.36% (above 0%: growing)	95.97%	9.72%	Compare
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)
RLMD Relmada Therapeutics, Inc.	$341.3M	— (loss-making)	—	—	n/m	−50.06% (below 0%: shrinking)	0.00%	0.00%	Compare
IRD Opus Genetics, Inc.	$336.9M	— (loss-making)	— (loss-making)	−73.80% (below 0%: shrinking)	n/m	−16.37% (below 0%: shrinking)	100.00%	(2,182.78%)	Compare
ENTA Enanta Pharmaceuticals, Inc.	$334.1M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$343.2M	—	—	−10.80%	—	−21.12%	71.59%	0.00%

All 614 Biotechnology stocks →